Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia
Journal Article
·
· J. Clin. Invest.; (United States)
Approximately two-thirds of patients who receive the anticancer drug gallium nitrate develop mild hypocalcemia. To evaluate the mechanism of drug-induced hypocalcemia, we tested the effects of gallium nitrate upon in vitro release of /sup 45/Ca++ from explanted fetal rat bones. The drug significantly inhibited /sup 45/Ca++ release in response to stimulation with both parathyroid hormone and a lymphokine preparation with osteoclast activating factor activity. The inhibitory effects on bone resorption were both time- and dose-dependent. Later, in a pilot study, we treated 10 patients who had cancer-related hypercalcemia with gallium nitrate administered by continuous infusion. All patients responded by a reduction of total serum calcium to normal or subnormal concentrations (13.8 +/- 1.05 mg/dl, mean +/- SD pretreatment, to 8.03 +/- 1.03 mg/dl, mean posttreatment nadir). Our results indicate that gallium nitrate effectively treats cancer-related hypercalcemia and that it probably acts by inhibiting calcium release from bone.
- Research Organization:
- Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York
- OSTI ID:
- 6748012
- Journal Information:
- J. Clin. Invest.; (United States), Journal Name: J. Clin. Invest.; (United States) Vol. 73:5; ISSN JCINA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells
Interleukin 1 synthesis by a transitional cell carcinoma: relationship to bone resorption and humoral hypercalcemia of malignancy
Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent)
Journal Article
·
Sun Mar 31 23:00:00 EST 1985
· J. Clin. Invest.; (United States)
·
OSTI ID:5123983
Interleukin 1 synthesis by a transitional cell carcinoma: relationship to bone resorption and humoral hypercalcemia of malignancy
Conference
·
Fri Feb 28 23:00:00 EST 1986
· Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States)
·
OSTI ID:5383571
Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent)
Journal Article
·
Wed Nov 09 23:00:00 EST 1983
· N.Engl. J. Med.; (United States)
·
OSTI ID:7011611
Related Subjects
560305 -- Chemicals Metabolism & Toxicology-- Vertebrates-- (-1987)
560306* -- Chemicals Metabolism & Toxicology-- Man-- (-1987)
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKALINE EARTH ISOTOPES
ANIMALS
ANTINEOPLASTIC DRUGS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL EFFECTS
CALCIUM 45
CALCIUM ISOTOPES
CHEMOTHERAPY
DAYS LIVING RADIOISOTOPES
DRUGS
EVEN-ODD NUCLEI
FETUSES
GALLIUM COMPOUNDS
GALLIUM NITRATES
HORMONES
INTERMEDIATE MASS NUCLEI
ISOTOPES
MAMMALS
NITRATES
NITROGEN COMPOUNDS
NUCLEI
OXYGEN COMPOUNDS
PARATHORMONE
PATIENTS
PEPTIDE HORMONES
RADIOISOTOPES
RATS
RODENTS
SIDE EFFECTS
THERAPY
UPTAKE
VERTEBRATES
560306* -- Chemicals Metabolism & Toxicology-- Man-- (-1987)
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKALINE EARTH ISOTOPES
ANIMALS
ANTINEOPLASTIC DRUGS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL EFFECTS
CALCIUM 45
CALCIUM ISOTOPES
CHEMOTHERAPY
DAYS LIVING RADIOISOTOPES
DRUGS
EVEN-ODD NUCLEI
FETUSES
GALLIUM COMPOUNDS
GALLIUM NITRATES
HORMONES
INTERMEDIATE MASS NUCLEI
ISOTOPES
MAMMALS
NITRATES
NITROGEN COMPOUNDS
NUCLEI
OXYGEN COMPOUNDS
PARATHORMONE
PATIENTS
PEPTIDE HORMONES
RADIOISOTOPES
RATS
RODENTS
SIDE EFFECTS
THERAPY
UPTAKE
VERTEBRATES